Corporate-News

Title: announce of the registration of INJEX Pharma USA in Miami, Florida
Date: Mar 2012
Textkörper:

INJEX Pharma AG is thrilled to announce the registration of INJEX Pharma USA in Miami, Florida. This will allow INJEX Pharma to begin the sale and marketing of the needle free injection device INJEX 30 in the USA.

Marketing and sales of the innovative injection without needle INJEX, is expected to begin in the spring 2012. Our new office is expected to open soon.

The USA market is huge, with more than 40 million diabetics, 250,000 dentists, 500,000 MD's and 180,000 beauticians. The new company will create strong affiliations with solid distribution partners in the US. Negotiations were started months ago and it is expected, that first orders will be delivered in the next months.

The INJEX 30 is a CE approved medical device and the company will announce shortly corporate news about the FDA 510(k) registration.

The new INJEX Pharma USA is headed by International Sales Director, Mr. Sylwin Grinman, who has been responsible for acquiring new exclusive distributor agreements, which was signed for in other big markets like China, India, Brazil, Canada etc.

According to Mr. Grinman:

'USA/ North America is a powerful market for any new and unique technology that wants to establish its potential in its respective marketplace.

We are blessed to have the INJEX technology. This needle free injection system will create remarkable changes for all people who fear needles and alleviate the stress and anxiety associated with traditional needle and syringe. Its applications are numerous and constantly emerging, ranging from dentistry, doctors who use local anesthesia, cosmetology, diabetics who use insulin or other medication that is self-administered, such as growth hormones and heparin. INJEX is a high technology device. It is simple, easy to use and will fit perfectly into the American lifestyle.'

Title: renaming to INJEX PHARMA AG
Date: Feb 2012
Textkörper:

The District Court of Berlin Charlottenburg confirms the renaming of Paketeria AG to INJEX PHARMA/

INJEX Pharma AG has scheduled  for a higher listing in the Entry Standard at the Frankfurt Stock Exchange

 

The renaming of Paketeria AG to INJEX PHARMA AG and additional resolutions regarding the general meeting, were published by the District Court of Berlin in Charlottenburg.

In 2012, INJEX PHARMA AG wants to secure a major worldwide role and become a prominent leader in the technology of needle free injection technology as compared to other international competitors.

The supervisory board is examining which stock exchange segment INJEX PHARMA could match.  A swift change to the entry standard (Open Market) is planned, with the possibility of a transfer to a higher segment.

The company has therefore decided to remain in the stock market and to create a securities prospectus.   Together with the prospectus and segment change, it allows the company to adjust the equity story and to seek strong partners on an international campaign to shape the future of the market.  INJEX PHARMA AG and its shareholders will benefit from the increased transparency and improved liquidity of the securities.  With the renaming and the planned segment changes, a new chapter for the company and its shareholders is unfolding.

„ With the new company name INJEX Pharma AG and the planned change on a higher segment at the Frankfurt Stock Exchange we open a new chapter for the company and our shareholders. “ Our goal is to succeed in placing the equity story of INJEX PHARMA AG in a preeminent place internationally. In addition to enhancing our position on a worldwide level, we aim to provide innovation and high quality standards in a growing international market, “ stated Andy Rösch, CEO of INJEX Pharma AG .

Title: INJEX at Arab Health
Date: Jan 2012
Textkörper:

The injection without needle, INJEX took great interest at the Arab Health. The company Boubyan Medical, official distributor for middle east represented INJEX on the arabien health-trade-show from january 23 till 26. The benefits of a „syringe without needle“ where brought closer to a large number of interested parties.
 

Title: distribution agreement for middle east
Date: Jan 2012
Textkörper:

INJEX Pharma signs an exclusive distribution agreement with Al-Shamali Group for the needle-free syringe INJEX30 for the Middle East.


INJEX Pharma GmbH has expanded recently its signed contract with Al-Shamali GROUP Co. (BOUBYAN MEDICAL) for the needle-free syringe INJEX30 for the entire Middle East.

 

Centralized marketing, led by a strong partner in the Middle East region, will ensure a stable and continuous pricing policy, as well as a uniform marketing appearance.  Partners in these countries will rely on the centrally created promotional material, such as brochures and TV spots, and thus aims to enhance synergies.

A central warehouse will be set up in Dubai enabling the partners to place orders with relative ease. INJEX Pharma can supply its customers at short notice with the added advantage of low cost transport by ship. The general manager, Dr. Wael Elghamri of Boubyan Medical (The pharmaceutical division of Al-Shamali Group) has initiated various registrations processes with the national Ministry of Health (MOH) Among these countries are: Kuwait, UAE, Qatar, Jordan, Lebanon, Oman, Bahrain, Egypt and the Kingdom of Saudi Arabia. An initial order has been confirmed and is on its way to distributors. The order will reach them before the ARAB HEALTH Fair in Dubai begins.
 
'We are very pleased that the Middle East is now guided by the successful and centrally managed marketing of INJEX30.  For all participants, this advantage of local collaboration will improve and generate greater value added within this area “said Andy Rösch, CEO of Paketeria AG / INJEX Pharma AG.”

The rate of diabetes in the Middle East is one of the highest in the world. Ten million people have diabetes and 1.5 million of these patients need an insulin injection daily.  The Al-Shamali Group’s objective is to operate in this region and to achieve approximately 25% of the market share in the next three years
 
The INJEX Pharma GmbH was merged into Paketeria AG to 100% at the shareholders annual meeting on the 16th of December.  The official statement of the change of name is expected shortly from the district court from Berlin.

Title: Annual Shareholder Meeting
Date: Dec 2011
Textkörper:

The Annual Shareholder Meeting of the new INJEX Pharma AG in Berlin  ended up successfully

The projected figures for 2012 INJEX – The  needle-free syringe – are increasing

The Annual Shareholder Meeting of Paketeria AG took place on the 16th of December. All decisions were approved by nearly 100% of the shareholders after a presentation by the CEO, Mr Andy Rösch.

In accordance with the decisions reached, Paketeria will be renamed as INJEX Pharma AG. The INJEX Pharma AG will take over all shares (100%) in INJEX Pharma GmbH. As part of the capital increase the number of shares will reach approx 3.3 million shares. This was based on an expert evaluation which was presented by an independent auditor and the relevant district court. The enterprise value was based on audited figures of 11.2 million Euro based on November 2011 data.

Forecast figures for 2012 will be adjusted upward. A turnover of approximately 40 Million Euro and an income before tax of 3.7 million € are expected. The increase is due to a new agreement and a strong partnership with the outermost region in the Middle East. The company will be informing the shareholders separately about these measures.  

The CEO reported over the previous procedures of insolvency and the role of the Volksbanken, cooperative unions and consulting department of the Institutes, GenoConsult GmbH. Most shareholders were appalled and angry.

Detailed information about production, which has been running since October was reported. The  5 million euro financing offer from New York is not yet been used, MMB Medical Marketing Berlin GmbH has secured the finances with the support of business partners and thus prevented the company stock from any further dilution.

Mr. Rosch reported further on ongoing negotiations with pharmaceutical and generic companies later this week. Negotiations are taking place with two companies before Christmas.  Furthermore, a new application for a new use of intra-dermal injection was introduced. This option opens up extensive opportunities and negotiations with pharmaceutical companies. The described application is also an opportunity that paves the way for painless needle-free Botox injections in the future.

Extensive information about the Annual Shareholder Meeting and further details will be published in further press releases. Investor relations should be strengthened worldwide to make international investors and promoters aware of the company’s potential and to optimize existing relationships.

The general annual meeting was held with the participation of a representative from the Protection of Investors Association (SDK). His questions were fully answered in detail and in a positive manner

The end of the event became lively and the Shareholders were thrilled and enthusiastic as Mr Rösch gave the shareholders a needle free and painless injection!

Title: contract with Kuwait
Date: Nov 2011
Textkörper:

Paketeria AG: INJEX Pharma GmbH signed first contract with Kuwait in Middle East for sales of the innovative needle free drug delivery system INJEX30

INJEX Pharma will start to deliver very soon the first shipment of their needle free and painless syringe INJEX30 to the Middle East to Kuwait. INJEX Pharma GmbH signed an exclusive distributor contract with Al SHAMALI GROUP Co.(BOUBYAN MEDICAL) from Sharq-Kuwait.

 

In Middle East the diabetes rate is among the highest in the world. The people do not have enough exercise, people smoke, obesity is increased and nutrition sweet and unhealthy. Africa, the Middle East and India have the highest increasing prevalence worldwide.

 

The Al Shamali Group signed pre contracts for other countries in Middle East. The registration for the product is expected short term. The pharmaceutical division manager Dr. Wael A. Elghamri is responsible for the market introduction.

 

Al-Shamali Group for General Trading & Contracting was established in Kuwait City, the State of Kuwait in 1992. Over the past two decades it has grown from its humble sole focus on construction to a very diverse group of companies encompassing International Investment, Medical & Pharmaceuticals.'

 

Mr. Ali A. Reda, the General Manager for Al-Shamali Group Co. stated that 'INJEX is a unique instrument that will make a big difference and a relief from needle shots for Diabetic patients in Kuwait and other countries in the region. As one patient feedback after receiving and testing a starter kit sample was 'IT IS MAGIC' Dr. Wael A. Elghamri, Pharmaceutical Division Manager (Boubyan Medical), stated: 'From our studying in our area diabetes rate is among the highest in the world, we have more than 20% of population patients with diabetes, more than 18% of them are insulin dependent. In addition we see other treatments of INJEX30 like immunization, local anesthesia and meso - therapy. So we expect very high sales at launch.'

 

Andy Rösch, CEO of Paketeria AG (INJEX Pharma AG): 'We are very convinced that this agreement is just the very first step with the INJEX30, made in Germany, into the Middle East Area. We have a lot of other interested companies from Middle East, who are interested to market our needle free syringe. Last week we trained directly after MEDICA our potential new partner for Saudi Arabia and we expect the contract to be signed before Christmas' INJEX Pharma GmbH shall be merged by 100 % into Paketeria AG, listed at the Frankfurt Stock Exchange, which is the main resolution on the Annual Meeting of December 16th 2011 in Berlin. Paketeria AG will have the new company name INJEX Pharma AG.

Title: exclusive distributor agreement for India
Date: Nov 2011
Textkörper:

INJEX Pharma GmbH and GenTech Laboratories LTD signed exclusive distributor agreement for INJEX, the syringe without a needle, for India

Another important milestone for INJEX Pharma to become the worldwide market leader in 2012

 

INJEX Pharma based in Berlin is confirming, that the company signed an exclusive agreement for sales and marketing of the needle free drug delivery system INJEX 30. The partner is GENTECH Laboratories LTD, based in Mumbai.  Both parties agreed to keep information about the planned revenues confidential.

 

India is worldwide the country with the second highest population in the world with 1.2 Billion people. The gap between rich and poor people is existing, geographic size in very special, lot of people living in areas of high population density like Mumbai, New Delhi etc. Therefore the marketing activities will be very focused.

 

Start of sales is expected for beginning of 2012. Registration of the INJEX 30 is ongoing. Both companies believe that the INJEX-system has interesting perspectives in India, taking into consideration the strongly growing number of patients with type II diabetes.

 

Mr. Viraj Gandhi, Managing Director GENTECH Laboratories LTD stated: “India is the diabetes capital of the world with more than 60 million diagnosed cases as of 2010. Injex needle free delivery system will be a welcome relief to type 1 diabetes patients who have been poking themselves with a syringe for years. We are very excited about the Injex needle free syringe and its potential in India”

 

Gandhi and his family have been involved in the Indian pharmaceutical industry for the last 30 years. At some stage in the last few decades they have been involved in every aspect of the pharmaceutical industry value chain: manufacturing, marketing, distribution and retailing.

 

The INJEX System from the Berlin manufacturer INJEX Pharma GmbH offers the needle free and painless subcutaneous injection of drugs. The main user groups are diabetics, who have to inject insulin a few times every day and for doctors and for end users for injection of growth hormones, thrombosis prophylaxis, local Anestheticsfor surgical and dental application, vaccinations, cancer treatment etc.

 

INJEX Pharma GmbH shall be merged by 100 % into Paketeria AG, listed at the Frankfurt Stock Exchange, which is the main resolution on the Annual Meeting of December 16th 2011 in Berlin. Paketeria AG will become INJEX Pharma AG.

Title: new Start as a listed company
Date: Nov 2011
Textkörper:

INJEX Pharma GmbH – Friendly Takeover and new Start as a listed company INJEX Pharma AG

With the needle free syringe INJEX, INJEX Pharma AG plans to become the first profitable company worldwide in  “Needle Free Drug Delivery“ in 2012

 

The Berlin based company INJEX Pharma GmbH has developed a needle free and painless syringe for injection of various medicines. After having taken several strategic measures INJEX Pharma GmbH will be merged through a capital increase with Paketeria AG, which is listed on the Frankfurt Stock Exchange. After the annual meeting of Paketeria AG on December 16th, the company will be 100 % owned by Paketeria AG, which will change the company name to INJEX Pharma AG. CEO is the founder of the INJEX business, Mr. Andy Rösch.

 

INJEX Pharma will begin with no debt, fully paid production assembly lines and an inventory value of 3 Million €. 2011 Sales and marketing activities have proven very successful and various exclusive distributor agreements were signed worldwide. Preliminary calculations show that the company reached the breakeven point on a monthly basis in October 2011.

 

“Needle Free Drug delivery Technology“ has existed for more than 25 years and it is estimated that worldwide, an investment of more than 1 Billion Euros has been spent for R & D by several international companies. Today the excitement for a “needle free future“ is still high. The market value of competitors is considerably high despite producinglarge losses.

INJEX Pharma has the advantage that the company has no inherited debt and a very low cost structure.  The outlook for success is excellent based on these fundamentals and the company has a clear focus for 2012: To become worldwide the first profitable company in “Needle Free Drug Delivery“ and by doing so, exciting shareholders with a new market capitalization.

Title: takeover of INJEX Pharma GmbH
Date: Sep 2011
Textkörper:

Successful takeover of INJEX Pharma GmbH, needle free syringe, by MMB Medical Marketing Berlin GmbH / Paketeria AG

INJEX Pharma will be merged with Paketeria AG, which just recently announced the withdrawal of insolvency

 

MMB Medical Marketing Berlin GmbH announces the 100 % take over of Injex Pharma GmbH. Injex Pharma owns the worldwide rights to the innovative needle-free injection technology, the full automation assembly production lines and inventory with a value of a few million Euros. (Distributor purchase price).

MMB is planning to merge Injex Pharma with Paketeria AG, which announced the withdrawal of insolvency a short time ago.

Under the management of Mr. Jim Fukushima, Injex Pharma mainly delivered disposables to existing INJEX users and had no active marketing or sales activities. Marketing and sales were performed successfully by MMB starting at the end of last year, MMB signed several exclusive agreements with distributors from a variety of diverse countries. These exclusive contracts shall be transferred to Paketeria AG as part of the deal.

The purchase price of 2.4 Million Euro will be implemented in installments in accordance with the achievement of certain milestones. A first payment was wired before the signatures by MMB.

 

Jim Fukushima and Andy Rösch have been involved and engaged with INJEX for more than 12 years.  Directly related to this long relationship, a win/win solution was found and a deal was signed.  The assets of Injex Pharma, such as worldwide rights, production lines, tools as well as existing inventory, combined with the revenues and profits from signed and expected new exclusive distributor agreements by MMB has created promising prospects for the future under the roof of Paketeria AG.

The purchase contract was signed last Friday, September 2th. The former owner and managing director, Mr. Jim Fukushima stated: "Andy and I have a long relationship based on the innovative product INJEX. The sale of Injex Pharma to MMB is a huge opportunity for INJEX and the chance for me to concentrate on a project involving a needle-free injection technology with prefilled ampoules. We, Andy and I, will be in close communication about these extra market opportunities."

Andy Rösch stated: "After the final end of insolvency of Paketeria AG, this is another important milestone for our planned future of Paketeria AG. I want to thank Jim Fukushima, who opened up all the future chances with a very special and unusual purchase agreement. We understand the next tasks and challenges: Merging INJEX in Paketeria AG and the restart of production under the QM regulations of ISO for medical devices and sterile products. "

Title: Paketeria AG- Insolvency proceedings regarding the assets of the Berlin Company Paketeria AG has been repealed:
Date: Aug 2011
Textkörper:

August 17, 2011

Paketeria AG- Insolvency proceedings regarding the assets of the Berlin Company Paketeria AG has been repealed:

The Chief Executive Officer of Paketeria AG, Andy Rösch, received the final ruling regarding insolvency proceedings of Paketeria AG from the District Court of Charlottenburg yesterday.

The ruling reads as follows:

'The insolvency proceedings concerning the assets of the Paketeria Aktiengesellschaft, Buckower Damm 114, 12349 Berlin, represented by Andy Rösch, has been repealed by the legal confirmation of the insolvency plan according to §258 1 InsO.'

The MMB Medical Marketing Berlin GmbH submitted to the insolvency administrator an offer to creditors in summer 2010.

At the August 2010 creditors meeting, 95% of the creditors voted in favour of the of afore mentioned offer . The insolvency withdrawal is a direct result of the immediate complaint and legal appeal filed by the GenoConsult GmbH almost 1 year ago.

The Paketeria AG will work closely with the Supervisory Board regarding any and all further action to be taken. This should be achieved by integrating the business content of MMB into Paketeria AG by a planned capital increase.

The Paketeria added value concept for banks will be offered under a fair partnership as a shop in bank model.

Paketeria AG will comprehensively inform stockholders about all further steps to be taken. As a first step, the quota for creditors shall be deposited.

http://medical-marketing-berlin.com/files/Paketeria_AG_Aufhebung_Insolve...

 

Alle News ...